Thursday, 28 May 2020

International Picture Archiving and Communications Systems Market 2019 Estimation And Forecasts Up To 2023

Market Scenario:
Radiology imaging solutions have generated a significant return on its healthcare IT investment by implementing Exa’s Voice Recognition in place of traditional transcriptionists, and their productivity has increased by 400%.           
Picture Archiving and Communication System (PACS) is a modality of the medical imaging technology used specifically for image transmission from the site of image acquisition to other locations. The technology is convenient to access multiple modalities such as radiographs, CT scan, MRI, ultrasound, and others.
It is noted that the increasing prevalence of chronic diseases and the growing geriatric population are the key factors driving the PACS market. The increasing burden of chronic diseases has been observed in different parts of the world. Population in the low socio-economic group is mostly found to get affected by these chronic diseases. According to the report published in the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults are dealing with at least one type of cardiovascular disease. The prevalence of type-2 diabetes, obesity, and cardiovascular diseases has increased rapidly in the recent years, suggested by a study published in the BMC Public Health in 2017.
Various other factors such as supportive investments and funds provided by government and private bodies, rising demand for early diagnosis, technological advancements in the medical imaging devices, rising incidence of cancer, improving regulatory framework, growing research funding, unmet medical needs, rising competition among market players, and increasing government assistance are continuously contributing to the growth of the global PACS market.
Despite these drivers, there are some issues associated with the PACS market. The high cost associated with the technology, lack of healthcare insurance, lack of awareness, and poor healthcare system in low- and middle-income countries may hamper the growth of the market.
It is estimated that the Picture Archiving and Communications Systems (PACS) market growth is expected to boost at a CAGR 7.0% during the forecast period of 2017–2023.
Key Players
Some of the key players in the global Picture Archiving and Communications Systems (PACS) market are Advanced Data Systems, Agfa-Gevaert N.V., Allscripts Healthcare Solutions, Inc., ALTA VISTA TELERADIOLOGY, Argus Radiology, Avreo, Inc., Brit Systems, Comarch SA, Cybernet Medical Corporation, FujiFilm Medical Systems, GE Healthcare, Global Diagnostics, INFINITT Healthcare, Konica Minolta Healthcare Americas Inc., McKesson Corporation,Inc., ONRAD, Inc., Pacshealth, LLC, PERFECT IMAGING, LLC, RamSoft, Inc., Radiology Imaging Solutions, Scimage, Inc., Sectra Imtec AB, Sectra Imtec AB, Siemens Healthineers, Singular Medical Technologies, StatRad, LLC, Telediagnostics Services Pvt. Ltd., Telerad Tech Private Limited, Virtual Radiology (vRAD), and others
Segmentation
The global Picture Archiving and Communications Systems (PACS) market is segmented on the basis of type, component, imaging type, delivery mode, and end-user.
On the basis of the type of imaging type, the market is classified as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), nuclear imaging, X-ray, and ultrasound.
On the basis of end-user, the market is classified as hospitals and clinics, healthcare centers, imaging centers, diagnostic centers, clinical research institutions, and others.
On the basis of delivery mode, the market is classified as cloud-based (SAAS) delivery mode, web-hosted (On-Demand) delivery mode, and on-premise mode.
On the basis of type, the market is classified as oncology PACS, cardiology PACS, dental PACS, orthopedics PACS, and others.
On the basis of components, the market is classified as hardware, software, and services. The hardware segment is further classified as access devices, peripherals, servers, storage devices, and networking devices. The services segment is further classified as consulting, implementation services, post-sales and maintenance services, and training services.
Regional Analysis
Asia Pacific is the fastest growing Picture Archiving and Communications Systems (PACS) market owing to a huge patient pool, increasing demand for diagnosis, and development in the healthcare IT sector. According to IBEF, the Healthcare Information Technology (IT) market was valued at USD 1 billion in 2016 which is estimated to grow 1.5 times by 2020.
The Americas dominates the Picture Archiving and Communications Systems (PACS) market owing to the rising demand for early diagnosis, rising prevalence of chronic diseases, well-developed technology, high healthcare expenditure, and the presence of leading players. Owing to the rising demand for imaging devices, various market players are coming up with advanced technology. For instance, on March 26, 2018, Singular Medical Technologies (SMT), the U.S. based technology company announced two new additions to its PACStation suite of products. The PACStation-GO is a fully functional reading workstation, with two full-size diagnostic monitors and is completely portable.
Europe holds the second position in the Picture Archiving and Communications Systems (PACS) market. It is expected that the funding towards research and development expenditure and increasing competition among marketers are likely to drive the European market.
The Middle East and Africa holds the lowest share of the global Picture Archiving and Communications Systems (PACS) market due to low development, lack of technical knowledge, and poor medical facilities.

Posted by at No comments:

Acute Sinusitis Market 2023 – Market Size, Share, Trends Analysis And Growth Forecast

Synopsis of the Global Acute Sinusitis Market
The Acute Sinusitis Market is mainly driven by the increasing prevalence of sinusitis across the globe and the increasing demand for diagnostic services. Additionally, technologically advancement and development in healthcare and upcoming Acute Sinusitis Market trends are also the factors driving the market growth. However, there is a need to create awareness about the disease and its diagnosis, especially, in the developing countries.
Also known as acute rhinosinusitis, acute sinusitis causes inflammation and swelling of cavities around the nasal passage. It is mostly caused by the common cold. Nasal obstruction, drainage of a thick, yellow or greenish discharge and pain, tenderness, and swelling around the nose, eyes, and forehead are the major symptoms of acute sinusitis. Other symptoms of the disease are ear pressure, bad breath, headache, cough, aching in your upper jaw and teeth, fatigue, and fever. The complications due to acute sinusitis are found to be less common. However, chronic sinusitis, meningitis, partial or complete loss of sense of smell, and vision problems are some of the major complications.
Global acute sinusitis market is expected to grow at a CAGR of 6.2% during the forecast period.
Key Players       
Some of the key players in this market are Sanofi (France), Abbott (U.S.), Bayer AG (U.S.), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), Merck & Co, Inc. (U.S.), AstraZeneca Plc (U.K), Reddy’s Lab (India), Novartis AG (Germany), and others.
Segmentation                                                                                                                                            
The global acute sinusitis market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the market is segmented into nasal endoscopy, imaging tests, laboratory tests, and allergy testing. Imaging tests are further segmented into CT scan and MRI.
On the basis of treatment, the market is segmented into saline nasal spray, nasal corticosteroids, decongestant, OTC pain relievers, allergy shots, antibiotics, and others.
On the basis of end-user, the market is segmented into hospitals and clinics, research centers, and others.
Regional Analysis
The Americas leads the global acute sinusitis market with North America being the largest. The rising prevalence of chronic diseases in the U.S. and technological advancements in diagnostic testing fuel the growth of the market in North America. According to the Center for Disease Control and Prevention (CDC), in the U.S., 29.4 million people suffer from acute sinusitis. Additionally, there is an increase in the direct spending by the U.S. population for sinusitis management including medications, outpatient and emergency department visits, and ancillary tests and procedures.
Europe is the second largest market for acute sinusitis. The increasing demand for laboratory test and allergy testing, with an increase in various types of laboratory testing fuel the growth of the market. Furthermore, there are various other factors driving the growth of the market such as increasing focus on diagnostic testing for both acute and chronic illnesses and increasing expenditure on research and development activities by countries such as Germany, France and the U.K. Additionally, the increasing focus on development of innovative technologies and overall growth of healthcare diagnostics in this region also contribute to the growth of the market.
The Asia Pacific acute sinusitis market is expected to exhibit a huge growth potential which is mainly driven by the increasing awareness about acute sinusitis and the increasing demand for a skin test for its diagnosis. Furthermore, the increasing demand for laboratory testing devices and a huge development in the medical device sector fuel the growth of the market in this region. Additionally, the market is also driven by the increasing focus of key players on targeting major geographies in Asia Pacific such as India, Australia, and the Republic of Korea. Additionally, the increasing number of patients suffering from acute sinusitis and the availability of various treatment options for the disease drive the growth of the market.  India, China, and Japan are the major contributors to the growth of the market due to an increase in the number of healthcare institutes such as hospitals and clinics and availability of skilled workforce.
In the Middle East, the market is mainly driven by the increasing importance of diagnosis and treatment for sinusitis and the growth of the healthcare industry in countries such as the United Arab Emirates (U.A.E.) and Saudi Arabia. In Africa, the demand for primary care services and the increasing prevalence of acute and chronic diseases are the major factors driving the market growth.
Posted by at No comments:

World Cord Blood Banking Services Market Top Key Players Shares, Revenue, Analysis And Forecasts To 2023

Market Scenario:
The global cord blood banking services market is expected to exhibit a robust 11.4% CAGR over the forecast period from 2017 to 2023, according to a new report from Market Research Future (MRFR). The global cord blood baking services market is likely to be driven by the growing research into the medical utility of stem cells and cord blood, and the growing establishment of the infrastructure required to create a strong cord blood banking services network.
The umbilical cord blood is a rich source of stem cells and can treat more than 80 genetic diseases. The stem cells also can treat long-lasting diseases such as diabetes, cancer, immune diseases, and blood diseases. Even though a small amount of cord blood can be collected from a single umbilical cord, it comprises a large number of stem cells which can be cultivated and stored for the future use. These cells are collected from hospitals and nursing homes after delivery and stored in cord blood banks (average of 20–25 years) for future use.
Currently, the companies are trying to intensify the awareness about the benefits of cord blood storage. For instance, in 2014, the Institute for Transfusion Medicine and Cord Blood Registry pooled their resources to launch a multi-year initiative for increasing the awareness of cord blood cells.
Factors such as increasing application of cord blood in the treatment of chronic conditions, increasing the focus of federal agencies to set up public banking units, growing awareness regarding this treatment line, and increasing number of facilities across the region are driving the market growth. However, the high cost and probability of non-usage, along with the recommendation driven market by gynecologists are factors hampering the of the Cord Blood Banking Services market growth.
Key Players
Some of the key players in the global cord blood banking services market are China Cord Blood Corporation (China), Cord Blood America, Inc. (U.S.), CBR Systems, Inc. (U.S.), Cordlife Group Limited (Singapore), Cryo-Cell International, Inc. (U.S.), Cryo-Save AG (Netherland), ViaCord, Inc. (U.S.), Virgin Health Bank (Qatar), California Cryobank Stem Cell Services LLC (U.S.), StemCyte, Inc. (India), Norton Healthcare, Inc. (U.S.), Lifeforce Cryobank Sciences Inc. (U.S.), CordVida (Brazil), CryoHoldco de Latinoamerica, S.A.P.I. De C.V. (Mexico), Vita 34 International (Germany), Maze Cord Blood Laboratories (U.S.), The University of Colorado Cord Blood Bank (U.S.), CorCell (U.S.), Lifebank USA (U.S.), Cryoviva Biotech Pvt. Ltd (India), Genecord (U.S.), AlphaCord (U.S.), FamilyCord (U.S.), Cells4Life (UK), Michigan Blood (U.S.), CariCord (U.S.), LifeCell International Pvt. Ltd (India), Stem Cell Cryobank Inc. (U.S.), Viacord Processing Laboratory (VPL) (U.S.), New Jersey Cord Blood Bank (U.S.), Carter BloodCare (U.S.), Americord Registry (U.S.), and others.
Segmentation
The global cord blood banking services market has been segmented on the basis of storage service, component, application, and end-user.
On the basis of storage service, the global cord blood banking services market can be segmented into public cord blood banks, private cord blood banks, and hybrid cord blood banks.
On the basis of application, the global cord blood banking services market can be segmented into cancers, blood disorders, metabolic disorders, immune disorders, and osteoporosis.
On the basis of component, the global cord blood banking services market can be segmented into cord blood, cord tissue, placenta, and others.
On the basis of end-user, the global cord blood banking services market is segmented into hospitals (medical applications), pharmaceutical research (drug discovery), research institutes (scientific research), and others.
Regional Analysis                     
The global cord blood banking services market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global cord blood banking services market owing to the growing number of service providers, increasing awareness about the long-term benefits of cord blood storage, growing investments in public banking, and reduction in the cost involved in storage. Moreover, the U.S. contributes to a significant market share for the global cord blood banking industry. Factors such growing per capita income, increasing number of storage service providers, and high adoption rate for advanced technologies attributed to the largest market share.
The European cord blood banking services market is the second largest market followed by the Asia Pacific region. The Asia Pacific region is expected to dominate the global cord blood banking services market in terms of growth rate during the forecast period. Though the region presently grasps a minimal share in the global market; it is anticipated to exhibit an enormous growth potential owing to the increasing awareness of stem cell banking and vast improvement in health care reforms in countries such as Malaysia, India, Indonesia, and China. Besides, Asia Pacific is a relatively untapped regional market in comparison with developed regions, which is also a reason why it grants better opportunities for the growth of companies.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Posted by at No comments:

World Emphysema Market Estimation Of Top Key Players Shares, Revenue, Analysis And Forecasts Till 2023

Synopsis of Global Emphysema Market
Emphysema, a lung disease is characterized by the shortness of breath, thereby, damaging the air sacs in the lungs. The disease leads to rupture and weakening of inner walls of the air sacs over the period. The disease involves the reduction in the surface area of the lungs which in turn reduces the amount of oxygen reaching the bloodstream. Hence, during exhalation, the alveoli do not function properly leaving the air trapped in the lungs, leaving no space for oxygen-rich air to enter the lungs. Emphysema and chronic bronchitis are together known as the Chronic Obstructive Pulmonary Disease (COPD). The patients suffering from emphysema also have chronic bronchitis. The major causes of emphysema are exposure to air pollutants, chemical fumes, and dust and smoking. The condition can be diagnosed through various tests such as imaging tests that include chest X-ray and CT scan and the lung function test.
The global emphysema market is mainly driven by the high prevalence of respiratory diseases such as chronic bronchitis, emphysema, and others and a huge demand for treatment including smoking cessation drugs and antibiotics. Additionally, the rising availability of diagnostic services for respiratory illness also fuels the growth of the market.
According to the World Health Organization, COPD affects nearly 210 million people which is attributed to the increasing population in urban areas across the globe and growing number of tobacco smokers.
The global emphysema market size is expected to grow at a CAGR of 6.1% during the forecast period.
Segments                                                                                                                        
The global emphysema market segments on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market is segmented into centrilobular and panlobular emphysema.
On the basis of diagnosis, the market is segmented into imaging test, lung function test, and others. The imaging test is further segmented into chest X-ray and CT scan.
On the basis of treatment, the market is segmented into medications, therapy, and surgery. Medications are further segmented into smoking cessation drugs, bronchodilators, inhaled steroids, antibiotics, and leukotriene modifiers. Therapy is further segmented into pulmonary rehabilitation, nutrition therapy, gene therapy, and supplemental oxygen. Surgery is further segmented into lung volume reduction surgery, lung transplant, and bullectomy.
On the basis of end-user, the market is segmented into hospitals and clinics, surgical centers, and others.
Regional Analysis of the Global Emphysema Market               
The American emphysema market is segmented into two regions, namely, North America and South America. North America, being the largest market, is mainly driven by the increasing use of imaging test and lung function test for the diagnosis of the disease and huge population base diagnosed with COPD. Furthermore, the U.S. is the largest market in North America owing to the presence of large number of market players manufacturing medications for emphysema and increasing awareness about risk factors and cases of the disease. The American Lung Association stated that in the U.S., COPD is the fourth leading cause of deaths. Canada is expected to be the fastest growing market which is driven by the overall increasing demand for diagnostic medical devices with progress in the medical device sector. South America is expected to be the fastest growing market due to technologically advanced devices for diagnosis and the increasing demand for treatment options of respiratory diseases
The European emphysema market exhibits a positive growth with an increasing emphasis on the diagnosis of chronic respiratory conditions such as the COPD and asthma and increasing focus on research and development activities for the treatment of respiratory diseases. Germany and the U.K. are the major contributors to the growth of the market. Additionally, increasing expenditure in healthcare by major countries in Europe also accelerates the growth of the market.
Asia Pacific is expected to be the fastest growing market whose growth is attributed to a huge demand for lung function test and other diagnostic tests and the increasing focus on early diagnosis and treatment of lung diseases. Furthermore, other factors contributing to the growth of the market are lifestyle changes, the influence of western culture among the adults, and addiction to smoking. Additionally, rising environmental pollution and exposure to harmful chemicals also attribute to the growth of the market.
The Middle Eastern and African market for emphysema exhibits a steady rise with an increase in the number of healthcare facilities providing treatment for the chronic condition and the flourishing growth of medical device sector especially the diagnostic devices such as MRI and CT. In the African region, the awareness about COPD is increasing and is fueling the growth of the market.
Key Players in the Global Emphysema Market
Some of the key players in this market are Intrexon Corporation, Pulmonx Inc., Halozyme Therapeutics, Inc., Mariposa Health Limited, PneumRx, Uptake Medical Corporation, Icure Pharmaceuticals, Inc., Pfizer, Inc., BTG International’s, Olympus Corporation, Kamada Limited, Emphasys Medical, Inc. and others.
Posted by at No comments:

Amblyopia Market Worldwide Key Players Forecasts By Revenue, Growth Rate Till 2023

Amblyopia is an eye disorder which leads to decreased vision in one or both the eyes due to suppressed input from the brain. The most common cause of amblyopia is a refractive error in one or both eyes, or it might even occur due to muscle imbalance. The other cause of amblyopia is if the infant is born with a cataract, which causes cloudy images. There are four types of amblyopia, namely, Strabismus Amblyopia, Refractive Amblyopia, Deprivation Amblyopia, and Reverse Amblyopia. The global prevalence rate of Amblyopia is 2 to 3% of the infant population. Amblyopia market is driven by growing incidence of ophthalmological disorders such as cataracts, macular degeneration, glaucoma, and refractive errors. According to reports published by the United Kingdom Statistics Authority, in 2015, around 15,900 people were registered as visually impaired. Moreover, according to the Journal of Ophthalmology, as of 2014 there were around 28 million visually impaired people in the European region. With the increasing prevalence, there is increasing in the advancement of treatment and hence influencing the growth of the Amblyopia market size. 
Amblyopia, commonly known as lazy eye, is a vision impairment disorder, in which one or both the eyes have reduced or no vision. Amblyopia can begin during infancy or early childhood. Amblyopia requires detection and diagnosis early in childhood, which otherwise can lead to blindness during later life. On the basis of type, amblyopia can be divided into, Strabismic amblyopia, Refractive amblyopia, Deprivation amblyopia, and Reverse Amblyopia.
Global amblyopia market is expected to grow at a CAGR of 3.80% during the forecast period 2017-2023.
Key Players                                                                                                         
  • Amblyoptica (Holding) Pty Ltd,
  • Amblyotech, Inc,
  • Good-Lite Co,
  • Vivid Vision, Inc.,
  • Cooper Vision,
  • Johnson & Johnson,
  • Novartis AG.,
  • Carl Zeiss AG,
  • HOYA Corporation,
  • Krafty Eye Patches¸
  • Fresnel Prism and Lens Co.,
  • Hilco Vision,
  • McKesson Corporation
Segmentation                      
The global amblyopia market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis the type, it is segmented into strabismus amblyopia, refractive amblyopia, deprivation amblyopia, reverse amblyopia, and other.
On the basis of the diagnosis, it is segmented into visual acuity tests, photo screening, Bruckner test and others.
On the basis of the treatment, it is segmented into eye patches, atropine drops, glasses, video game and others.
On the basis of the end-user, it is segmented into hospitals & pharmacies, ophthalmic clinics, and others.
Regional analysis
The global amblyopia market, on the basis of region, is divided into the Americas, Europe, Asia Pacific and the Middle East & Africa. The Americas accounted for the largest amblyopia market share of 37.9% in 2016 for global amblyopia market. This large share is majorly attributed due to the increasing prevalence of ophthalmological disorders, the presence of major manufacturers, increasing technological advancement and high healthcare expenditure. Europe accounts for the second largest market share, whereas Asia Pacific is expected to grow at the fastest rate with 4.35% CAGR for the forecast period. With lots of opportunity and continuously growing economies, the presence of huge patient population, rapid development in technology and presence of a huge opportunity for the development the region is expected to be the fastest growing region. The Middle East & Africa is growing at a slow pace, and the low income accounted for the least market share in 2016 but is expected to grow in the coming future.
Posted by at No comments:

Blood Testing Market Expects An Extensive Growth In Roi Till 2023

Blood Testing is a laboratory analysis technique that is performed based on the blood sample taken from patient's body through a finger prick or syringes to determine the state of the health. The abnormal functioning of organs can be determined by Blood Testing. These tests are affordable and are commonly performed in hospitals and clinics as a primary checkup for identifying any mild to serious ailments which influence the growth of the Blood Testing market.
The Global market for Blood Testing is expected to grow at a CAGR of approximately 5.5% during 2017 to 2023.
Key Players:
The global blood Testing market growth is led by some of the fervent players including Baxter International (US), Abbott Laboratories Inc. (US), Gen-Probe, Inc. (US), Becton Dickinson & Company (US), Novartis Diagnostics (US), Biomerica, Inc. (US), Cepheid Corporation (US), Meridian Bioscience, Inc. (US), Trinity Biotech (US), Siemens Healthcare (Germany), Bio-Rad Laboratories Inc. (US), Grifols (Spain), bioMérieux (France), Nanosphere Inc. (US), Roche Diagnostics (Switzerland), Bruker Corporation (US), Alere Inc. (US), Thermo Fisher Scientific Inc. (US) Cardinal Health (US), Beckman Coulter (US), Danaher Corporation (US), and Trividia Health (US)
Industry, Innovation & Related News
September 07, 2018 – Scientists in Australia published their study of a novel blood test they have developed in the JCI Insight Journal. The new blood test that can potentially identify whether a person who had a heart attack in the past is at high risk of having another one. certain lipid biomarkers or fats in the blood to improve upon traditional risk factors in predicting heart disease. The researchers hope to trial it in Australia in the next two to three years.
August 13, 2018 – Engineering for All (Israel), announced the development of a handheld programmable device, named as RevDx (Revolution Diagnostics) that performs automated blood analysis and diagnostics at the point of care. RevDx is meant for anyplace without reliable access to a lab, electricity or Internet connection.
Market Drivers
Growing incidents of chronic diseases and conditions such as cancer, diabetes, heart disease along with the organ failure cases drive the demand for blood testing in multiplications. Needless to say, that the blood testing market is ever increasing. Also, great technological strides being made in electronic monitoring devices and substantial investments transpired into R&D activities are in turn, paying off well, expanding the market size.
Additional factors supporting the market growth include the ever-increasing population that is getting inclined towards the sedentary lifestyle and urbanization. Improving economic conditions are rapidly availing access to the excellent health care, increasing the healthcare expenditures and eventually the market growth.
Conversely, lack of awareness towards the availability and advantages of blood testing is obstructing the market growth.  Also, the unmet clinical needs coupled with the unavailability of external funding; especially in the developing regions are obstructing the market growth. Nevertheless, increasing demand for personal & hand-held diagnostic devices & augmenting demand for the blood testing in the diagnostics that can give fastest & accurate results is fostering the market growth.
Segmentation
The global Blood Testing market has been segmented on the basis of test type, disease, method, and end-user.
On the basis of test type, the global Blood Testing market can be segmented into glucose testing, lipid panel testing, direct LDL testing, Prostate Specific Antigen (PSA) testing, Blood Urea Nitrogen (BUN) testing, A1C testing, high sensitivity C-Reactive Protein (hs-CRP) testing, Vitamin D testing, alt testing, thyroid stimulating hormone testing, creatinine testing, serum nicotine/cotinine testing, AST testing, cortisol testing, testosterone testing, and others.
On the basis of disease, the global Blood Testing market can be segmented into anemia, infection, leukemia, hypokalemia, kidney disorders, heart attack, coronary heart disease, and other diseases.
On the basis of method, the global Blood Testing market can be segmented into manual blood culture testing and automated blood culture testing.
The automated blood culture testing segment is classified into automated blood culture system, blood culture instruments, and others      
On the basis of end-user, the global Blood Testing market is segmented into hospitals, clinics, diagnostic centers, research labs, and others.
Regional Analysis                     
The global Blood Testing market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global Blood Testing market owing to the rising incidence of diseases such as kidney disorders, blood stream infections, other infections, high demand for rapid diagnostic tests, and growing aging population.
The European Blood Testing market is the second largest market owing to the increasing awareness of chronic infection diseases due to the initiatives undertaken by private companies, government organizations, and educational institutions.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to the increasing awareness of the importance of diagnostics in personalized medicines and due to government initiatives, that promote the use of personalized medicines. Furthermore, the increase in a number of government schemes to curb the rising healthcare expenditures in emerging economies is expected to drive the regional market growth.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Competitive Analysis
The blood testing market appears fragmented and fiercely competitive due to many large and small players churning the competition in the market.  Through the strategic partnership, acquisition, expansion, product & technology launch, and collaboration, these players try to gain the competitive edge.
Posted by at No comments:

Global Chordoma Disease Market Growth Factors, Types And Application By Regional Analysis 2023

Market Scenario
Chordoma is a rare, slow-growing type of bone cancer. The increasing awareness programs about cancers led by WHO and UNICEF and the rising healthcare investment in the emerging markets are anticipated to exhibit more opportunities for the growth of the chordoma disease market trends.
The global chordoma disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global chordoma disease market is segmented into biopsy, imaging, blood tests, and others. The imaging segment is further divided into x-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Positron Emission Tomography (PET) scanning, and bone scan.
On the basis of treatment, the global chordoma disease market is segmented into chemotherapy, radiation therapy, cryosurgery, surgical treatments, radiosurgery, targeted therapy, and others. The surgery segment is further classified into radical resections, sacral chordoma, spinal chordoma, skull base chordoma, and others. The chemotherapy segment is classified into methotrexate, doxorubicin, and others. Furthermore, the targeted therapy segment is divided into bevacizumab, erlotinib, and others.
On the basis of end-user, the global chordoma disease market is segmented into hospitals, clinics, cancer care centers, and others.
Regionally, the Americas chordoma disease market is segmented into two major regions, namely, North America and South America.
The Americas region holds the largest share of the global chordoma disease market owing to the increasing demand for targeted therapies and growing health concerns. As per an estimate by the American Cancer Society, about 3,300 new cases of bone cancer were diagnosed in 2016 with a death toll of about1490. Thus, the high prevalence of chondroid chordomas is the major hurdle in the market growth.
Key Players
Some of the key players in the global chordoma disease market are AstraZeneca plc (U.K.), Amgen, Inc. (U.S.), Actavis plc (U.S.), Bristol-Myers Squibb and Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Novartis International AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Debiopharm Group (Switzerland), Bayer AG (Germany), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Optivus Proton Therapy, Inc. (U.S.), ProCure Treatment Centers, Inc. (U.S.), Varian Medical Systems, Inc.(U.S.), Amura Holdings Ltd. (U.S.), Catena pharmaceuticals Inc. (U.S.), Celldex therapeutics Inc. (U.S.), Eckert & Ziegler BEBIG (Germany), Infinity Pharmaceuticals (U.S.), Medivir AB (Sweden), Merrion Pharmaceuticals Plc. (U.S.), and others.
Regional Analysis                    
The global chordoma disease market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global chordoma disease market owing to the high prevalence of bone cancer in the region and aging population, along with high favorable reimbursement policies in the region. As per the American Cancer Society in 2017, about 3,260 people are projected to be diagnosed with primary bone cancer in the U.S. (1,820 men and boys and 1,440 women and girls).
The European chordoma disease market is anticipated to emerge as the second largest market owing to the development of the pharmaceutical and medical industries. According to the Cancer Research U.K. organization in 2014, about 580 new cases of bone sarcoma were found in the U.K.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to less awareness regarding bone cancer among the population and less availability of effective treatment option for bone cancer in the region. For instance, in September 2016, Dr. Reddy's Laboratories entered into a strategic collaboration with Amgen for marketing and distributing Prolia (denosumab), Vectibix (panitumumab), and Xgeva (denosumab) in India.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Posted by at No comments:
Subscribe to: Posts (Atom)